Patents by Inventor Christie SCHULTE

Christie SCHULTE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MRGX2 ANTAGONISTS
    Publication number: 20220112174
    Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
    Type: Application
    Filed: October 4, 2021
    Publication date: April 14, 2022
    Inventors: Edward BRNARDIC, Michael BURY, Rodolfo CADILLA, Jon COLLINS, Yu GUO, Anthony HANDLON, Huijie LI, Yue LI, Daniel PAONE, Christie SCHULTE, Barry SHEARER, Guosen YE, Maben YING, Huichang ZHANG
  • Chemical Compounds
    Publication number: 20220009918
    Abstract: A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: November 6, 2019
    Publication date: January 13, 2022
    Inventors: Rodolfo Cadilla, David Norman Deaton, Andrew L. Larkin, Christie Schulte, Terrence L. Smalley
  • CHEMICAL COMPOUNDS
    Publication number: 20210238162
    Abstract: The present invention relates to compounds of Formula (XI): wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 15, 2016
    Publication date: August 5, 2021
    Inventors: Rodolfo CADILLA, David Norman DEATON, Ashley Paul HANCOCK, Heather HOBBS, Simon Teanby HODGSON, Andrew L. LARKIN, Joelle LE, Paul N. MORTENSON, Daniel J. PRICE, Gordon SAXTY, Lee T. SCHALLER, Christie SCHULTE, Ian Edward David SMITH, Stephen Andrew THOMSON, Joseph Wendell WILSON
  • 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
    Patent number: 11053234
    Abstract: A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 6, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: David Norman Deaton, Yu Guo, Ashley Paul Hancock, Christie Schulte, Barry George Shearer, Emilie Despagnet Smith, Eugene L. Stewart, Stephen Andrew Thomson
  • 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS
    Publication number: 20190241554
    Abstract: A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: October 12, 2017
    Publication date: August 8, 2019
    Inventors: David Norman DEATON, Yu GUO, Ashley Paul HANCOCK, Christie SCHULTE, Barry George SHEARER, Emilie Despagnet SMITH, Eugene L. STEWART, Stephen Andrew THOMSON
  • CD38 inhibitors and methods of treatment
    Patent number: 9840496
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 12, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: J. David Becherer, Rodolfo Cadilla, David Norman Deaton, Curt Haffner, Brad Richard Henke, Frank Preugschat, Christie Schulte
  • CD38 INHIBITORS AND METHODS OF TREATMENT
    Publication number: 20170260164
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: September 14, 2017
    Inventors: J. David BECHERER, Rodolfo CADILLA, David Norman DEATON, Curt HAFFNER, Brad Richard HENKE, Frank PREUGSCHAT, Christie SCHULTE